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Conclusion 
In this study, we demonstrated patterns of LN involvement 
based on PET-imaging. In the pelvis, various 
recommendations are largely consistent and all LNs were 
covered by the recommended CTVs. LN “misses” appear 
generally cranially (common iliac or para-aortic) or 
caudally (inguinal) to the recommended CTVs. The 
established guidelines differ significantly, particular 
regarding the inguinal region. Based on our results, we 
finally presented our recommendation for contouring of 
the elective CTV of the inguinal region. Lymph node 
involvement of a larger number of patients should be 
investigated to enable final recommendations. 
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Purpose or Objective 
The utilization of taxanes has demonstrated promising 
results in squamous cell carcinoma of the head and neck 
(SCCHN) as induction chemotherapy prior to definitive 
chemoradiotherapy (CRT). The purpose of this 
multicenter, phase 3 trial was to investigate whether the 
incorporation of concurrent paclitaxel and cisplatin 
together with a slightly reduced total dose of radiotherapy 
(RT) is superior compared with standard fluorouracil-
cisplatin based CRT. 
Material and Methods 
Previously untreated patients with non-metastatic SCCHN, 
stage III-IVB, were randomized to receive 
paclitaxel/cisplatin(PacCis)-CRT (arm A; paclitaxel 20 
mg/m2 on days 2, 5, 8, 11 and 25, 30, 33, 36; cisplatin 20 
mg/m2, days 1-4 and 29-32; RT to a total dose of 63.6 Gy) 
or fluorouracil/cisplatin(CisFU) -CRT (arm B; fluorouracil 
600 mg/m2 ; cisplatin 20 mg/m2, days 1-5 and 29-33; RT: 
70.6 Gy). Primary endpoint was 3-year-disease free 
survival (3y-DFS). Secondary endpoints included overall 
survival (OS), locoregional failure rate (LFR), distant 
failure rate (DFR), and toxicity. 
Results 
 A total of 221 patients have been enrolled in 14 sites 
between 2010 and 2015. With a median follow-up of 3.7 
years, 3y-DFS in the CisFU arm and PacCis arm was 58.2% 
and 48.4%, respectively (HR 0.82, 95% CI 0.56-1.21, 
p=0.52). The 3y-OS amounted to 64.6% in the CisFU arm, 
and to 59.2% in the PacCis arm (HR 0.82, 95% CI 0.54-1.24, 
p=0.43). There were no significant differences for LFR and 
DFR. In the subgroup of p16-positive oropharyngeal 
carcinomas, 3y-DFS and 3y-OS was 84.6% vs 83.9% 
(p=0.653), and 92.3% vs. 83.5% (p=0.76) in arm A and B, 
respectively. Hematological toxicities grade 3-4 were 
significantly reduced in arm A (anemia, p=0.01; 
leukocytopenia, p =0.003).  
 
 
 
Conclusion 
Paclitaxel/cisplatin-CRT with a slightly reduced total RT-
dose is not superior to standard fluorouracil/cisplatin-
CRT. Subgroup analyses indicate that a reduced radiation 
dose seems to be sufficient for p16+ oropharyngeal cancer 
and/ or in non-smokers.  
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Purpose or Objective 
The DAHANCA9 hyperfractionation study and the MARCH 
meta-analysis (Bourhis et al, Lancet 2006) on altered 
fractionation showed that Hyperfractionated Accelerated 
Radiotherapy (HART) is superior in terms of loco-regional 
control (LRC) and overall survival (OS) compared to 
conventional or moderately accelerated radiotherapy for 
Head and Neck Squamous Cell Carcinomas (HNSCC). Since 
2007, HART has been included as a treatment option in the 
Danish DAHANCA radiotherapy guidelines. The aim of the 
present study was to evaluate this treatment strategy 
using LRC, OS and late morbidity as endpoints. 
Material and Methods 
Prospectively registered patients (pts) with HNSCC treated 
with HART according to national guidelines prescribed as 
76Gy/56fx, 10 fx/week, as primary treatment were 
identified in the DAHANCA database and updated. The 
study was evaluated as intention to treat and elective 
neck-dissection was not an option. 
Results 
From July 2007 to December 2017, 271 pts with HNSCC 
treated with HART were identified in four national cancer 
centers that on a regular basis offers HART according to 
treatment guidelines. The median age was 64 years (32-81 
years) and 74% were males. The majority of pts were WHO 
PS 0-1 (94%) and only 6% were WHO PS ≥2. Most (84%) were 
current or previous smokers with a smoking history of 
median 42 pack-years (1-140 pack-years). The primary site 
was larynx in 65 cases (24%); 176 cases were in the pharynx 
(65%) and 30 pts had oral cavity cancer (11%). In total, 62% 
of the cases were stage III-IV (UICC7). In the pharynx, 138 
cases (78%) were of oropharyngeal origin and of those, 48% 
were HPV/p16+. The proportion of pts receiving HART as 
planned was 96%. No patients received adjuvant or 
concomitant chemotherapy. As per September 1st 2018, 50 
loco-regional failures (19% of the pts) were detected with 
a median follow-up time of 29 months: 47 occurred in T-
site and 15 in N-site. Among those, 12 pts had both T- and 
N-site failure.Three-year actuarial LRC was 81% and OS 
was 68%. LRC at three years was significantly different for 
stage I-II and stage III-IV HNSCC (90% vs. 74%, HR 0.44 
(range 0.23-0.81)) but not significantly better for 
HPV/p16+ oropharyngeal carcinomas compared to the 
HPV/p16- oropharynx pts (94% vs 89%).The proportion of 
pts reporting severe late dysphagia was 16%, and 9% 
reported late, severe dryness of the mouth; 8% were 
observed with late tardive edema of the larynx, 10% with 
severe mucosal atrophy and 5% with severe fibrosis of the 
subcutaneous tissue in the neck region. 
Conclusion 
Hyperfractionated accelerated radiotherapy is an 
attractive treatment approach in patients with HNSCC. 
Three-year loco-regional control as observed in this study 
is more than 80% and that is reflected in an acceptable 
overall survival. In this study, HART produced equally good 
results for HPV/p16+ and HPV/p16- oropharyngeal cancer 
patients. Severe late morbidity is reasonably low and 
comparable to treatment with chemo-radiotherapy. 
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Purpose or Objective 
Due to a risk of occult nodal metastases in clinically node-
negative (cN0) head and neck squamous cell carcinoma 
(HNSCC) patients, prophylactic and often bilateral neck 
irradiation is mandatory. However, it leads to a large 
irradiation of healthy tissues and could miss unexpected 
nodal basins drained by the tumor. This prospective, non-
randomized, interventional phase II study investigated 
how sentinel lymph node (SLN) mapping by SPECT/CT may 
help to individualize prophylactic neck irradiation and its 
potential impact on radiation-related toxicities and tumor 
control. The final results are presented. 
Material and Methods 
Forty-four patients with newly diagnosed cN0 squamous 
cell carcinoma of the oral cavity, oropharynx, larynx or 
hypopharynx were included and treated with upfront 
(chemo)radiotherapy with a curative intent. After 
simulation, all patients were imaged in treatment position 
with SPECT/CT after 99mTc nanocolloid injection around 
the tumor. The neck levels containing up to four hottest 
SLN were selected for prophylactic irradiation (CTVn-LS). 
A comparative virtual planning was performed by including 
the levels selected on the basis of the current 
international guidelines (CTVn-IG). Dosimetric data to the 
different organs-at-risk (OAR) were compared between 
both plans. Normal tissue complication probability (NTCP) 
models for xerostomia and dysphagia as well as quality of 
life assessments (EORTC C30 and H&N35 scales) are being 
investigated to predict the clinical benefit of this 
technique.  
Results 
Lymphatic migration was observed in all of the 44 
patients. Four patients (9%) presented an unpredicted 
lymphatic drainage and 21 patients (48%) had only an 
unilateral drainage. The volumes of CTVn-LS and PTVn-LS 
(median volumes of 91.8 cc and 219.1 cc, respectively) 
were systematically smaller than CTVn-IG and PTVn-IG 
(median volumes of 188.3 cc and 405.3 cc, respectively). 
This led to a significant dose decrease in identified OAR, 
particularly to the controlateral parotid gland, 
controlateral submandibular gland, inferior constrictor 
muscle for oral/oropharynx tumors and superior 
constrictor muscle for larynx/hypopharynx tumors (Table 
1). NTCP values and QoL data processing is still work in 
progress and will be presented during the congress. At a 
median follow-up of 42 months, 3 patients experienced a 
regional relapse: 2 in an irradiated area (4.5%) and 1 in a 
non-irradiated area (2.3%). Currently, 4 patients had a 
local reccurence and 6 patients died (2 patients from 
geriatric degradation and 4 patients experienced fatal 
local relapse).  
 
 
 
Conclusion 
SLN mapping using SPECT/CT allowed to significantly 
reduce the prophylactically irradiated neck volumes in 
cN0 HNSCC patients. This resulted in a significant dose 
decrease in OAR, especially in patients presenting an 
unilateral lymphatic drainage, while uncompromising the 
